5th Circuit Blocks Mail-Order Abortion Pills Nationwide as Pro-Life Groups Set Demands for Makary's Replacement

Two Things Happened. Mainstream Coverage Is Treating Them as One.

Most outlets are covering the Makary resignation and the 5th Circuit abortion pill ruling as separate stories. They are not. They are the same pressure campaign arriving at two different institutions simultaneously — and together they represent the biggest shift in abortion drug policy since mifepristone was approved in 2000.

Here's what's actually new.

The 5th Circuit Ruling: What It Actually Says

On May 1, the U.S. Court of Appeals for the 5th Circuit temporarily reinstated a nationwide in-person dispensing requirement for abortion pills, according to CNN. The ruling came from a lawsuit filed by Louisiana against the FDA — not from federal regulatory action.

This detail is critical and largely overlooked in coverage.

The Trump administration's FDA, under Makary, had refused to reinstate that requirement through the regulatory process. Louisiana had to go to court to get what pro-life groups had been asking the executive branch to do for over a year.

The opinion was written by Trump-appointed Circuit Judge Kyle Duncan, joined by Judge Leslie Southwick (George W. Bush appointee) and Judge Kurt Engelhardt (Trump appointee), according to CNN. Mifepristone manufacturer Danco Laboratories immediately asked the court to pause its own ruling for seven days to allow an appeal.

Medication abortion now accounts for roughly two-thirds of all abortions in the United States, according to CNN. Louisiana argued that the FDA's mail-order rules were facilitating hundreds of abortions annually inside its borders, circumventing the state's post-Dobbs ban.

What Pro-Life Groups Are Demanding from Whoever Comes Next

SBA Pro-Life America president Marjorie Dannenfelser was specific on X: return immediately to the first Trump administration's in-person dispensing standard, end mail-order distribution of abortion drugs, and allow state laws to actually be enforced.

Sen. Josh Hawley went further in a statement reported by The Federalist. He accused Makary of four specific failures: attempting to place "pro-abortion lawyers" in key FDA positions, slow-walking a review of mifepristone, approving a new abortion drug — despite data showing it sends 1 in 10 women to the emergency room — and stonewalling Congress.

These are serious, specific charges rather than vague grievances.

The Numbers

The Guttmacher Institute — which is the abortion industry's own research arm — reported that more than 1.12 million abortions were performed in 2025. That is a 21% increase over 2020, the last full year before Roe was overturned, according to the Daily Wire.

The Supreme Court overturned Roe. Abortions went up.

Mail-order pills are the primary driver. Women in states with protective laws are obtaining mifepristone through telehealth visits with out-of-state providers and receiving pills by mail. The 5th Circuit ruling directly targets that mechanism.

What CNN's Coverage Left Out

CNN's reporting on the 5th Circuit ruling was technically accurate on the legal facts. But it framed the in-person dispensing requirement purely as an "access" issue, with zero mention of the 11 percent maternal injury rate tied to mifepristone that pro-life groups and Sen. Hawley have cited as the core public health justification for tighter restrictions.

If a drug sent 1 in 10 men to the emergency room, CNN would not frame restricting it as an "access" problem. The framing raises a question about consistency.

What Right-Leaning Coverage Left Out

The Federalist and thyblackman.com both framed Makary's exit as a straightforward pro-life victory. Neither pressed on a harder question: if the 5th Circuit had to do what the Trump FDA refused to do, what does that say about the administration's actual commitment to this issue — not just its rhetoric?

Pro-life groups voting for Trump in "numbers that mattered," as thyblackman.com noted, expected regulatory action. They got a court ruling instead. Those are not the same thing.

What the FDA Seat Actually Controls

Prescribing guidelines. Distribution rules. Drug approval authority. The FDA commissioner shapes abortion drug access in ways no single law can easily reverse — that's how federal regulatory power works.

The next commissioner will decide whether to reinstate REMS (Risk Evaluation and Mitigation Strategy) safeguards that were stripped under Biden. They will decide whether to conduct a genuine safety review of mifepristone. They will decide whether to approve or reject future abortion-related pharmaceuticals.

Trump has not announced a replacement as of this writing.

What Comes Next

A federal court just did what the Trump FDA refused to do — block nationwide mail-order abortion pills. Makary is gone. Pro-life groups have a specific, concrete list of demands for whoever sits in that chair next. Abortion numbers are rising, not falling, in the post-Dobbs era.

The next FDA commissioner is either the most important pro-life appointment Trump makes in his second term — or the next disappointment. The court handed the administration a framework. Now someone has to decide whether to use it.